Technology translation
Elastagen Pty Ltd, a clinical stage company developing medical device products based on recombinant tropoelastin and founded by Professor Tony Weiss, was sold for to Allergan plc in 2018 for a total of US$260M in contingent and commercial payments. The bulk of this delivers benefits to the University and Australia. Using our awarded patents, Allergan has commercially progressed Elastagen’s tropoelastin in clinical applications, including treatment for acne scars, stretch marks, aesthetic skin repair and surgical wound repair.